Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, GMU Form Proteomic-Based Cancer Biomarker Alliance

NEW YORK, March 28 (GenomeWeb News) - PerkinElmer and George Mason University will begin a five-year research collaboration to develop proteomic technologies and cancer biomarkers, the partners said today.

 

As first reported last week in ProteoMonitor, a GenomeWeb News publication, scientists from both organizations will work together to design new proteomic platforms for biomarker discovery.

 

The new technologies will operate on a "new concept ... that requires both the precise mass and the amino acid sequence of the candidate biomarker," said Emanuel Petricoin of George Mason.

 

The researchers will use PerkinElmer's Bioxpression platform for biomarker candidates and will be validated in clinical trials.

 

Financial details were not provided.

 

The research will focus on stage one lung, ovarian, and breast cancer.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.